# CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT04626752** · EARLY_PHASE1 · UNKNOWN · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** BCMA CAR-T
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04626752
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-01
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04626752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04626752, "CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04626752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*